Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction

Table 4

Biomarker concentrations stratified to left ventricular ejection fraction after one year.

Variable	()	()	value
Baseline biomarkers
Gal-3 (ng/mL)	7.1 (6.2-9.1);	7.1 (5.5-8.4);	0.34
sST2 (ng/mL)	24.5 (19.0-35.4);	24.0 (18.9-29.8);	0.37
hs-CRP peak (mg/dL)	6.3 (2.3-20.3);	2.7 (1.3-6.9);	0.01
Troponin I peak (ng/L)	69.7 (22.8-160.2);	14.4 (1.8-49.4);	<0.001
CK-MB peak (U/L)	135.0 (53.2-339.6);	46.5 (10.7-141.0);	0.01
NT-proBNP peak (pg/mL)	1921.5 (855.5-4262.0);	812.0 (287.5-1874.8);	0.01
Biomarkers at follow-up
Gal-3 (ng/mL)	9.3 (6.8-10.7);	7.8 (6.1-10.0);	0.17
sST2 (ng/mL)	30.3 (24.9-34.9);	30.1 (24.4-36.7);	0.45
Changes of biomarker concentrations
Change in Gal-3 (ng/mL)	1.7 (-0.7-3.5);	0.6 (-0.6-2.8);	0.24
Change in sST2 (ng/mL)	3.9 (-5.5-11.8);	5.4 (-2.7-13.2);	0.73

Bold values indicate values < 0.05. Changes were calculated as the one-year level minus the baseline level of each biomarker. CK-MB: creatine kinase-muscle/brain; Gal-3: galectin-3; hs-CRP: high-sensitivity C-reactive protein; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro-B-type natriuretic peptide; sST2: soluble interleukin-1 receptor-like 1.